NDA 217006 · Otsuka
Abilify Asimtufii
Aripiprazole · Intramuscular · Atypical Antipsychotic
Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 27, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
401
123 Phase 3, 18 recruiting
FAERS reports
42,627
36,055 serious, 3,410 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY ASIMTUFII is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death ( 5.1 ) ABILIFY ASIMTUFII is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )
What it is approved for
From the label in effect Apr 4, 2025.
ABILIFY ASIMTUFII is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults ABILIFY ASIMTUFII is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults ( 1 ) as maintenance monotherapy treatment of bipolar I disorder in adults ( 1 )
Mechanism: The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 28, 2025 Supplement 1 · Efficacy LetterLabel
- Apr 27, 2023 Original approval · Type 3 - New Dosage Form LetterLabelReview
2 products under this application
- ABILIFY ASIMTUFII · ARIPIPRAZOLE 960MG/3.2ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
- ABILIFY ASIMTUFII · ARIPIPRAZOLE 720MG/2.4ML (300MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- VA Augmentation and Switching Treatments for Improving Depression OutcomesPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01421342 · 1,522 participants · Start Dec 2012 · Primary completion Aug 2015
Drug: Switching: Bupropion-SR; Augmenting: Antidepressant + Bupropion-SR and 1 more · For: Major Depressive Disorder
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Tucson, Arizona · 35 sites in all
- A Study of Aripiprazole (Abilify) in Patients With Bipolar ManiaPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00261443 · 1,270 participants · Start Sep 2005 · Primary completion Jun 2009
Drug: Lithium or Valproate with placebo (PBO); Lithium or Valproate with Aripiprazole · For: Bipolar Disorder
Sites: Tuscaloosa, Alabama; Anaheim, California; Cerritos, California · 83 sites in all
- A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00095823 · 1,200 participants · Start Jun 2004 · Primary completion Aug 2006
Drug: Antidepressant + Placebo; Antidepressant + Aripiprazole · For: Major Depressive Disorder
Sites: Garden Grove, California; Northridge, California; Washington D.C., District of Columbia · 20 sites in all
- A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00237939 · 1,200 participants · Start Sep 2002 · Primary completion Nov 2006
Drug: Aripiprazole · For: Schizophrenia
Sites: Antwerp, Belgium; Brussels, Belgium; Diest, Belgium · 20 sites in all
- A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed EpisodePivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00277212 · 1,169 participants · Start Dec 1, 2005 · Primary completion Jul 1, 2009
Drug: Lamotrigine + Aripiprazole; Lamotrigine + Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 66 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,434
- off label use2,968
- product use in unapproved indication2,295
- drug interaction2,287
- weight increased2,186
- anxiety1,806
- condition aggravated1,714
- suicide attempt1,584
- fatigue1,553
- suicidal ideation1,456
- toxicity to various agents1,429
- nausea1,388
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 68 |
| 2005 | 111 |
| 2006 | 161 |
| 2007 | 217 |
| 2008 | 192 |
| 2009 | 256 |
| 2010 | 342 |
| 2011 | 354 |
| 2012 | 534 |
| 2013 | 428 |
| 2014 | 584 |
| 2015 | 1,211 |
| 2016 | 1,456 |
| 2017 | 2,955 |
| 2018 | 3,363 |
| 2019 | 3,484 |
| 2020 | 3,049 |
| 2021 | 3,704 |
| 2022 | 3,702 |
| 2023 | 4,183 |
| 2024 | 4,341 |
| 2025 | 4,314 |
| 2026 | 3,618 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Abilify Asimtufii (Aripiprazole)
2024 spending
$63.1M
Beneficiaries
3,361
11,621 claims
Per beneficiary
$18,785
$1,764.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $13,218,818 |
| 2024 | $63,138,033 |
Part B: Abilify Asimtufii (Aripiprazole) · HCPCS J0402
2024 spending
$89K
Beneficiaries
22
45 claims
Per beneficiary
$4,054
2024 ASP limit $5.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $89,191 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis.
Wang D, Schneider-Thoma J, Siafis S, et al. · Eur Neuropsychopharmacol 2024 · Systematic Review, Network Meta-Analysis
- Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Salazar de Pablo G, Pastor Jordá C, Vaquerizo-Serrano J, et al. · J Am Acad Child Adolesc Psychiatry 2023 · Systematic Review, Meta-Analysis
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.